|
| 37544828 | Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline. | | 2023 |
| 36306338 | Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination. | Blood advances | 2023 |
| 36241933 | Prescription appropriateness of anticoagulant drugs for prophylaxis of venous thromboembolism in hospitalized multimorbid older patients. | | 2023 |
| 36167324 | The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): A scoping review. | Haemophilia | 2023 |
| 36271487 | Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A. | Haemophilia | 2023 |
| 36436610 | Liver-related aspects of gene therapy for haemophilia: Call to action for collaboration between haematologists and hepatologists. | Journal of Hepatology | 2023 |
| 36423202 | IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy. | Haemophilia | 2023 |
| 37762470 | Genetic Variants Identified by Whole Exome Sequencing in a Large Italian Family with High Plasma Levels of Factor VIII and Von Willebrand Factor. | | 2023 |
| 37678546 | Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. | | 2023 |
| 37601023 | Erratum to 'A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays.' [Research and Practice in Thrombosis and Haemostasis Volume 7, Issue 3, March 2023, 100139]. | | 2023 |
| 37819168 | Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy. | | 2023 |
| 37646148 | Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study. | | 2023 |
| 37799090 | Clinical and Laboratory Presentation and Underlying Mechanism in Patients with Low VWF. | | 2023 |
| 37720483 | Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry. | | 2023 |
| 37694267 | Anti-emicizumab antibodies do not cross-react with mim8 . | | 2023 |
| 37548114 | Psychological and cognitive factors involved in decision-making process of haemophilia carriers in reproductive choices. | | 2023 |
| 37685542 | Characterization of Immunogenicity and Safety of COVID-19 mRNA-1273 in HIV-Positive Italian Patients with Hemophilia: A Prospective Single-Center Cohort Study. | | 2023 |
| 37287431 | International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors. | | 2023 |
| 36905699 | The role of anticoagulation clinics needs to be reassessed to include follow up of patients on direct oral anticoagulants. | | 2023 |
| 36835904 | Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs. | | 2023 |
| 36515623 | Air pollution and cardiovascular health in Middle East and North Africa: many shadows but some light. | | 2023 |
| 37468180 | Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists: reply. | | 2023 |
| 36897560 | Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies. | | 2023 |
| 36891522 | Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review. | | 2023 |
| 36823994 | Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial. | | 2023 |
| 36710195 | Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021. | | 2023 |
| 36580025 | A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study. | | 2023 |
| 36579445 | Covid-19 vaccination in patients with immune-mediated thrombotic thrombocytopenic purpura: a single-referral center experience. | | 2023 |
| 37204744 | Laboratory Testing for von Willebrand Factor Activity by a Glycoprotein Ib-Binding Assay (VWF:GPIbR): HemosIL von Willebrand Factor Ristocetin Cofactor Activity on ACL TOP. | | 2023 |
| 36951158 | Risk of relapse after SARS-CoV-2 vaccine in the Milan cohort of thrombotic thrombocytopenic purpura patients. | | 2023 |
| 37330268 | Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists: reply. | | 2023 |
| 37074987 | Opium as a risk factor for early-onset coronary artery disease: Results from the Milano-Iran (MIran) study. | | 2023 |
| 36877895 | Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura. | | 2023 |
| 36812433 | Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. | | 2023 |
| 36754679 | Genetic determinants of enhanced von Willebrand factor clearance from plasma. | | 2023 |
| 36700497 | Thromboplastin calibration revisited to look for possible revision of the World Health Organization recommendations. | | 2023 |
| 36700495 | Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists. | | 2023 |
| 37003290 | Fitusiran in haemophilia: a breakthrough drug with many unknowns. | | 2023 |
| 36798900 | Factor V Leiden but not the factor II 20210G>A mutation is a risk factor for premature coronary artery disease: a case-control study in Iran. | | 2023 |
| 37371855 | Laboratory Diagnosis of Antiphospholipid Syndrome in Anticoagulated Patients. | | 2023 |
| 36795341 | Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. | | 2023 |
| 36795343 | Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects. | | 2023 |
| 36792472 | von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. | | 2023 |
| 36735911 | Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. | | 2023 |
| 36539604 | Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism. | | 2023 |
| 36598379 | A retrospective study on the use of low-molecular-weight heparin for prevention of pregnancy-related recurrent venous thromboembolism and obstetrical complications. | | 2023 |
| 37515677 | Hemophilia patients: are they naturally anticoagulated? | | 2023 |
| 37505111 | Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy. | | 2023 |
| 35156839 | Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. | Human Gene Therapy | 2022 |
| 36313186 | Clinical and genetic determinants of the fatty liver-coagulation balance interplay in individuals with metabolic dysfunction. | JHEP Rep | 2022 |